Product
CD19/CD22-bispecific CAR-T cells
1 clinical trial
3 indications
Indication
B-cell Acute Lymphoblastic LeukemiaIndication
B-cell LymphomaIndication
Diffuse Large B-Cell LymphomaClinical trial
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia: a Prospective, Single-arm, Single-center, Phase 2 Clinical TrialStatus: Recruiting, Estimated PCD: 2025-12-31